Document And Entity Information
Document And Entity Information - USD ($) | 12 Months Ended | ||
Dec. 31, 2022 | Mar. 15, 2023 | Jun. 30, 2022 | |
Document Information [Line Items] | |||
Entity Central Index Key | 0001595248 | ||
Entity Registrant Name | Genprex, Inc. | ||
Amendment Flag | false | ||
Current Fiscal Year End Date | --12-31 | ||
Document Fiscal Period Focus | FY | ||
Document Fiscal Year Focus | 2022 | ||
Document Type | 10-K | ||
Document Annual Report | true | ||
Document Period End Date | Dec. 31, 2022 | ||
Document Transition Report | false | ||
Entity File Number | 001-38244 | ||
Entity Incorporation, State or Country Code | DE | ||
Entity Tax Identification Number | 90-0772347 | ||
Entity Address, Address Line One | 3300 Bee Cave Road #650-227 | ||
Entity Address, City or Town | Austin | ||
Entity Address, State or Province | TX | ||
Entity Address, Postal Zip Code | 78746 | ||
City Area Code | 877 | ||
Local Phone Number | 774-4679 | ||
Title of 12(b) Security | Common Stock, par value $0.001 per share | ||
Trading Symbol | GNPX | ||
Security Exchange Name | NASDAQ | ||
Entity Well-known Seasoned Issuer | No | ||
Entity Voluntary Filers | No | ||
Entity Current Reporting Status | Yes | ||
Entity Interactive Data Current | Yes | ||
Entity Filer Category | Non-accelerated Filer | ||
Entity Small Business | true | ||
Entity Emerging Growth Company | true | ||
Entity Ex Transition Period | true | ||
ICFR Auditor Attestation Flag | false | ||
Entity Shell Company | false | ||
Entity Public Float | $ 66,000,000 | ||
Entity Common Stock, Shares Outstanding | 51,974,078 | ||
Auditor Firm ID | 229 | ||
Auditor Name | Daszkal Bolton LLP | ||
Auditor Location | Boca Raton, FL |
Balance Sheets
Balance Sheets - USD ($) | Dec. 31, 2022 | Dec. 31, 2021 |
Current assets: | ||
Cash | $ 20,954,069 | $ 38,628,876 |
Accounts receivable | 34,852 | 0 |
Prepaid expenses and other | 484,224 | 511,348 |
Total current assets | 21,473,145 | 39,140,224 |
Property and equipment, net | 23,032 | 48,608 |
Other assets: | ||
Security deposits | 21,818 | 8,691 |
Supplies | 2,864,937 | 3,022,403 |
Intellectual property, net | 702,095 | 642,360 |
Total other assets | 3,588,850 | 3,673,454 |
Total assets | 25,085,027 | 42,862,286 |
Current liabilities: | ||
Accounts payables | 442,925 | 973,195 |
Other current liabilities | 2,367,362 | 612,100 |
Total current liabilities | 2,810,287 | 1,585,295 |
Stockholders' equity: | ||
Common stock $0.001 par value: 200,000,000 shares authorized; 48,105,962 and 47,874,708 shares issued and outstanding, respectively | 48,106 | 47,874 |
Additional paid-in capital | 125,054,453 | 120,316,315 |
Accumulated deficit | (102,827,819) | (79,087,198) |
Total stockholders' equity | 22,274,740 | 41,276,991 |
Total liabilities and stockholders' equity | $ 25,085,027 | $ 42,862,286 |
Balance Sheets (Parentheticals)
Balance Sheets (Parentheticals) - $ / shares | Dec. 31, 2022 | Dec. 31, 2021 |
Common stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Common stock, shares authorized (in shares) | 200,000,000 | 200,000,000 |
Common stock, shares issued (in shares) | 48,105,962 | 47,874,708 |
Common stock, shares outstanding (in shares) | 48,105,962 | 47,874,708 |
Statements of Operations
Statements of Operations - USD ($) | 3 Months Ended | 6 Months Ended | 9 Months Ended | 12 Months Ended | |||
Sep. 30, 2022 | Jun. 30, 2022 | Mar. 31, 2021 | Jun. 30, 2022 | Sep. 30, 2022 | Dec. 31, 2022 | Dec. 31, 2021 | |
Revenues | $ 0 | $ 0 | $ 0 | $ 0 | $ 0 | $ 0 | $ 0 |
Cost and expenses: | |||||||
Depreciation | 6,224 | 6,543 | 6,730 | 13,273 | 19,497 | 25,575 | 22,534 |
Research and development | 3,157,731 | 2,926,927 | 2,040,226 | 4,967,153 | 8,124,884 | 11,510,074 | 8,970,865 |
General and administrative | 3,006,484 | 2,836,916 | 3,263,741 | 6,100,657 | 9,107,141 | 12,295,070 | 11,676,703 |
Total costs and expenses | 6,170,439 | 5,770,386 | 5,310,696 | 11,081,083 | 17,251,522 | 23,830,719 | 20,670,102 |
Operating loss | (6,170,439) | (5,770,386) | (5,310,696) | (11,081,083) | (17,251,522) | (23,830,719) | (20,670,102) |
Interest income | 27,877 | 5,744 | 879 | 6,623 | 34,500 | 90,098 | 5,133 |
Net loss | $ (6,142,562) | $ (5,764,642) | $ (5,309,817) | $ (11,074,460) | $ (17,217,022) | $ (23,740,621) | $ (20,664,969) |
Net loss per share — basic and diluted (in dollars per share) | $ (0.13) | $ (0.12) | $ (0.11) | $ (0.23) | $ (0.36) | $ (0.50) | $ (0.44) |
Weighted average number of common shares — basic and diluted (in shares) | 47,952,100 | 47,097,251 |
Statements of Changes in Stockh
Statements of Changes in Stockholders' Equity - USD ($) | Common Stock [Member] | Additional Paid-in Capital [Member] | Retained Earnings [Member] | Total |
Balance (in shares) at Dec. 31, 2020 | 43,117,681 | |||
Balance at Dec. 31, 2020 | $ 43,118 | $ 89,295,601 | $ (58,422,229) | $ 30,916,490 |
Issuance of stock for cash (in shares) | 4,670,889 | |||
Issuance of stock for cash | $ 4,670 | 25,673,241 | 0 | 25,677,911 |
Issuance of stock for services (in shares) | 86,138 | |||
Issuance of stock for services | $ 86 | 155,959 | 0 | 156,045 |
Share based compensation | 0 | 5,191,514 | 0 | 5,191,514 |
Net loss | $ 0 | 0 | (20,664,969) | (20,664,969) |
Balance (in shares) at Dec. 31, 2021 | 47,874,708 | |||
Balance at Dec. 31, 2021 | $ 47,874 | 120,316,315 | (79,087,198) | 41,276,991 |
Net loss | (11,074,460) | |||
Balance at Jun. 30, 2022 | 32,411,285 | |||
Balance (in shares) at Dec. 31, 2021 | 47,874,708 | |||
Balance at Dec. 31, 2021 | $ 47,874 | 120,316,315 | (79,087,198) | 41,276,991 |
Net loss | (17,217,022) | |||
Balance at Sep. 30, 2022 | 27,488,515 | |||
Balance (in shares) at Dec. 31, 2021 | 47,874,708 | |||
Balance at Dec. 31, 2021 | $ 47,874 | 120,316,315 | (79,087,198) | 41,276,991 |
Issuance of stock for cash (in shares) | 120,859 | |||
Issuance of stock for cash | $ 121 | 6,305 | 0 | 6,426 |
Issuance of stock for services (in shares) | 110,395 | |||
Issuance of stock for services | $ 111 | 163,121 | 0 | 163,232 |
Share based compensation | 0 | 4,568,712 | 0 | 4,568,712 |
Net loss | $ 0 | 0 | (23,740,621) | (23,740,621) |
Balance (in shares) at Dec. 31, 2022 | 48,105,962 | |||
Balance at Dec. 31, 2022 | $ 48,106 | $ 125,054,453 | $ (102,827,819) | 22,274,740 |
Balance at Mar. 31, 2022 | 37,024,614 | |||
Net loss | (5,764,642) | |||
Balance at Jun. 30, 2022 | 32,411,285 | |||
Net loss | (6,142,562) | |||
Balance at Sep. 30, 2022 | $ 27,488,515 |
Statements of Cash Flows
Statements of Cash Flows - USD ($) | 12 Months Ended | |
Dec. 31, 2022 | Dec. 31, 2021 | |
Cash flows from operating activities: | ||
Net loss | $ (23,740,621) | $ (20,664,969) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Depreciation | 25,575 | 22,534 |
Share based compensation | 4,731,944 | 5,347,559 |
Changes in operating assets and liabilities: | ||
Accounts receivable | (34,852) | 127 |
Prepaid expenses and other | 27,125 | (126,795) |
Deposits | (13,127) | 2,050 |
Accounts payable | (530,269) | 780,226 |
Other current liabilities | 1,755,262 | 354,344 |
Net cash used in operating activities | (17,778,964) | (14,284,924) |
Cash flows from investing activities: | ||
Additions to property and equipment | 0 | (31,700) |
Additions to intellectual property | (59,735) | (40,735) |
Reductions (additions) to research and development supplies | 157,465 | (11,361) |
Net cash provided by (used in) investing activities | 97,731 | (83,796) |
Cash flows from financing activities: | ||
Proceeds from issuances of common stock | 6,426 | 25,677,911 |
Net cash provided by financing activities | 6,426 | 25,677,911 |
Net (decrease) increase in cash and cash equivalents | (17,674,807) | 11,309,191 |
Cash, beginning of year | 38,628,876 | 27,319,685 |
Cash, end of year | $ 20,954,069 | $ 38,628,876 |
Note 1 - Description of Busines
Note 1 - Description of Business and Basis of Presentation | 12 Months Ended |
Dec. 31, 2022 | |
Notes to Financial Statements | |
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] | Note 1 We are a clinical stage gene therapy company pioneering the development of gene-based therapies for large patient populations with unmet medical needs. Our oncology platform utilizes our non-viral ONCOPREX® Nanoparticle Delivery System. Using this system, plasmids containing tumor suppressor genes, which are deleted early in the development of cancer, are encapsulated within lipid nanoparticles and administered intravenously to the patient to re-express the deleted tumor suppressor genes. Our diabetes technology is designed to work in Type 1 2 Oncology Platform Our lead oncology drug candidate, REQORSA® Immunogene Therapy (generic name: quaratusugene ozeplasmid), previously referred to as GPX- 001, TUSC2. Acclaim – 1: 1 1/2 1 1 August 2022, 1 1 0.06 first 0.09 second December 2022, 0.09 second 0.12 third 0.12 one 1 2 "RP2D" 1 Acclaim – 2: 1 1/2 2 2 0.06 first 2 0.09 0.12 March 2023, 2 2023. RP2D. 2 The dose expansion portion of Acclaim- 2 2 1 2 RP2D 2 Acclaim – 3: November 2022, 1/2 3 not first 3 third 2023. The TUSC2 one 3 August 2022, TUSC2 Diabetes Gene Therapy In diabetes, we have exclusively licensed from the University of Pittsburgh of the Commonwealth System of Higher Education (“University of Pittsburgh”) multiple technologies relating to the development of a gene therapy product for each of Type 1 2 1 2 Pdx1 002 1 003 2 002 003 2023 August 2022, one 003 2 2023. February 2023, 1 002 16th 2023 Capital Requirements, Liquidity and Going Concern Considerations Our financial statements are prepared in accordance with U.S. generally accepted accounting principles ("GAAP") applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. However, as shown in the accompanying financial statements, we have sustained substantial losses from operations since inception and have no Management recognizes that we must obtain additional resources to successfully commercialize our intellectual property. To date, we have received funding in the form of equity and debt, and we plan to seek additional funding in the future. However, no not not |
Note 2 - Summary of Significant
Note 2 - Summary of Significant Accounting Policies | 12 Months Ended |
Dec. 31, 2022 | |
Notes to Financial Statements | |
Significant Accounting Policies [Text Block] | Note 2 Our financial statements have been prepared in accordance with GAAP. Accordingly, they do not not not Correction of Immaterial Error Subsequent to the issuance of the Company's 2021 March 30, 2022, not 2021. In accordance with Staff Accounting Bulletin (“SAB”) No. 99, No. 108, not not December 31, 2021 Balance Sheet As Previously Reported Adjusted As Revised Total assets 42,862,286 - 42,862,286 Total liabilities 1,585,295 - 1,585,295 Common stock 47,874 - 47,874 Additional paid-in capital 119,246,970 1,069,345 120,316,315 Accumulated deficit (78,017,853) (1,069,345) (79,087,198) Total stockholders' equity 41,276,991 - 41,276,991 For the Year ended December 31, 2021 Statement of Operations As Previously Reported Adjusted As Revised Revenues - - - Depreciation 22,534 22,534 Research and development 8,607,751 363,114 8,970,865 General and administrative 10,970,472 706,231 11,676,703 Total costs and expenses 19,600,757 1,069,345 20,670,102 Operating loss (19,600,757) (1,069,345) (20,670,102) Interest income 5,133 - 5,133 Net Loss (19,595,624) (1,069,345) (20,664,969) Loss per share (0.42) (0.02) (0.44) Weighted average common shares outstanding 47,097,251 47,097,251 Use of Estimates The preparation of our financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Cash We consider all highly liquid short-term investments with an initial maturity of three $250,000 December 31, 2022 December 31, 2021 Fair Value of Financial Instruments The carrying amounts reported in the balance sheet for cash, accounts receivable, accounts payable and accrued expenses approximate fair value because of the immediate or short-term maturity of these financial instruments. Accounting Standards Codification ("ASC") 820, 820’s 820 Level 1: Quoted prices for identical instruments in active markets. Level 2: Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not Level 3: Instruments with primarily unobservable value drivers. Property and Equipment Furniture and equipment are stated at cost. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets, which range from three five Research and Development Materials Costs Research and development expenditures consist of costs incurred to conduct research, develop engineering materials for further study, and develop clinical strategies for current and future programs. These costs include payments to collaborative research partners, manufacturing partners and consultants, and clinical strategy partners, wages and associated employee benefits, facilities, and overhead costs. These expenditures relate to our preclinical and Phase 1/2 Research and development supplies purchased and capitalized for future use were $2,864,937 and $3,022,403 at December 31, 2022 December 31, 2021 Intellectual Property Intellectual property consists of legal and related costs associated with patents and other proprietary technology and rights developed, acquired, licensed by, or maintained by us that we believe contribute to a probable economic benefit toward such patents and activities. These costs incurred in connection with obtaining and maintaining intellectual property protection, such as patent applications and patent maintenance, are capitalized. Intellectual property is stated at cost, to be amortized on a straight-line basis over the estimated useful lives of the assets. Accounting for Stock-Based Compensation We use the fair value-based method of accounting for stock-based compensation for options granted to employees, independent consultants and contractors. We measure options granted at fair value determined as of the grant date, and recognize the expense over the periods in which the related services are rendered based on the terms and conditions of the award. Generally, where the award only has a service condition, the requisite service period is the same as the vesting period. Long-Lived Assets We review long-lived assets and certain identifiable intangibles held and used for possible impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not December 31, 2022 December 31, 2021 Recent Accounting Developments Accounting pronouncements issued but not December 31, 2022 not |
Note 3 - Intellectual Property
Note 3 - Intellectual Property | 12 Months Ended |
Dec. 31, 2022 | |
Notes to Financial Statements | |
Intangible Assets Disclosure [Text Block] | Note 3 We own or have exclusive license agreements on 15 24 University of Pittsburgh On February 11, 2020, 1 2 first August 17, 2022, November 3, 2022, 1 On November 22, 2022, 1 On December 29, 2022, Pdx1 2 The University of Texas MD Anderson Cancer Center On May 4, 2020, |
Note 4 - Equity
Note 4 - Equity | 12 Months Ended |
Dec. 31, 2022 | |
Notes to Financial Statements | |
Stockholders' Equity Note Disclosure [Text Block] | Note 4 Registered Direct Offerings On February 10, 2021, See “Note 10 March 2023 March 2023 At-The Market Offering On November 18, 2022, may "2022 3 No. 333 239134 may December 31, 2022 2022 Stock Issuances During the year ended December 31, 2022 During the year ended December 31, 2021 Preferred Stock We are authorized to issue 10,000,000 shares of preferred stock at a par value of $0.001 per share, none December 31, 2022 Common Stock We are authorized to issue 200,000,000 shares of common stock at a par value of $0.001 per share, all of which is voting common stock. There were 48,105,962 shares of common stock outstanding at December 31, 2022 Common Stock Purchase Warrants Common stock purchase warrant activity for the years ended December 31, 2022 2021 Number of Warrants Weighted Avg. Exercise Price Outstanding at January 1, 2021 2,154,747 $ 4.37 Issued 50,000 5.29 Cancelled or expired — — Exercised — — Outstanding at December 31, 2021 2,204,747 $ 4.39 Issued 103,000 1.54 Cancelled or expired 146,326 3.79 Exercised 13,643 0.50 Outstanding at December 31, 2022 2,147,778 $ 4.32 Exercisable at December 31, 2022 1,901,945 $ 4.59 During the year ended December 31, 2022 November 2019 December 31, 2022 In the year ended December 31, 2021 December 31, 2021 2018 Our board of directors and stockholders have approved and adopted the Company’s 2018 “2018 April 3, 2018. 2018 422 1986, may may The number of shares of common stock reserved for issuance under the 2018 January 1 January 1, 2019 December 31 2018 January 1, 2021 2022, 2018 December 31, 2022 2018 2018 Our board of directors and stockholders approved and adopted the Company’s 2018 April 3, 2018. not may January 1 January 1, 2019, December 31 not January 1, 2022. Stock Options As of December 31, 2022 2018 2021. ten Expected term (in years): 10 Risk-free rate: 0.07% – 4.77% Volatility: 75.98% – 88.38% Dividend yield: 0% In the year ended December 31, 2022 In the year ended December 31, 2021 The weighted average remaining contractual term for the outstanding options at December 31, 2022 2021 Stock option activity for the years ended December 31, 2022 2021 Number of Shares Weighted Avg. Exercise Price Outstanding at January 1, 2021 6,844,069 $ 2.81 Options granted 2,519,628 4.26 Options exercised 670,889 1.01 Options expired 118,507 3.00 Outstanding at December 31, 2021 8,574,301 $ 3.35 Options granted 2,983,666 2.16 Options exercised 116,973 0.02 Options expired 66,667 2.55 Outstanding at December 31, 2022 11,374,327 $ 3.08 Exercisable at December 31, 2022 6,718,035 $ 3.23 Share-Based Compensation In the year ended December 31, 2022 December 31, 2022 not three December 31, 2022 As of December 31, 2022 not may In the year ended December 31, 2021 |
Note 5 - 401(k) Savings Transac
Note 5 - 401(k) Savings Transactions | 12 Months Ended |
Dec. 31, 2022 | |
Notes to Financial Statements | |
Defined Contribution Plan [Text Block] | Note 5 401 Transactions In 2022, 401 "401 401 401 401 December 31, 2022 |
Note 6 - Related Party Transact
Note 6 - Related Party Transactions | 12 Months Ended |
Dec. 31, 2022 | |
Notes to Financial Statements | |
Related Party Transactions Disclosure [Text Block] | Note 6 Introgen Research Institute Introgen Research Institute (“IRI”) is a Texas-based technology company formed by Rodney Varner, our President, Chief Executive Officer and Chairman of the Board and IRI's sole officer. IRI is owned by trusts of which Mr. Varner's descendants are the sole beneficiaries. In April 2009, August 2012, 2011 7 |
Note 7 - Commitments and Contin
Note 7 - Commitments and Contingencies | 12 Months Ended |
Dec. 31, 2022 | |
Notes to Financial Statements | |
Commitments and Contingencies Disclosure [Text Block] | Note 7 Leases On April 16, 2018, March 23, 2021, not April 30, 2021, 19 Commitments MD Anderson In July 2018, two May 2022. August 2022, three In 2011, 1994 On March 3, 2021, May 4, 2020, six one TUSC2 TUSC2 five six one five National Institutes of Health We have a royalty obligation to the National Institutes of Health ("NIH") to be paid upon our receipt of FDA approval using NIH technology. The $240,000 contingent obligation which increases annually by $20,000 and is $340,000 as of December 31, 2022 University of Pittsburgh Pursuant to an exclusive license agreement dated February 11, 2020 August 17, 2022, November 3, 2022, first three first first 1 20 first Pursuant to an exclusive license agreement dated November 22, 2022 first three first first 1 20 first Pursuant to an exclusive license agreement dated December 29, 2022 first three first first 2 20 first Contract Development and Manufacturing Organization We entered into a three July 2022 Contingencies From time to time, we may not |
Note 8 - Significant Events
Note 8 - Significant Events | 12 Months Ended |
Dec. 31, 2022 | |
Notes to Financial Statements | |
Effect of Covid 19 Pandemic [Text Block] | Note 8 The COVID- 19 may March 31, 2021, not 19 June 2021, 19 |
Note 9 - Income Taxes
Note 9 - Income Taxes | 12 Months Ended |
Dec. 31, 2022 | |
Notes to Financial Statements | |
Income Tax Disclosure [Text Block] | Note 9 The provision for income taxes differs from the amount computed by applying the statutory federal income tax rate to income before provision for income taxes. The sources and tax effects of the differences are as follows: Income tax provision at the federal statutory rate 21 % Effect of operating losses (21 )% 0 % At December 31, 2022 million not 2030. December 31, 2022 December 31, 2021 |
Note 10 - Subsequent Events
Note 10 - Subsequent Events | 12 Months Ended |
Dec. 31, 2022 | |
Notes to Financial Statements | |
Subsequent Events [Text Block] | Note 10 Reserves of 2018 2018 On January 1, 2023, 2018 February 16, 2023, no 2023 2018 no Share Issuances On January 1, 2023, January 2023, 2022 Option Issuances On January 17, 2023, January 23, 2023, January 30, 2023, 2018 Warrant Issuance On February 16, 2023, Restricted Stock Units On February 18, 2023, 2018 first second one one Executive Compensation On February 18, 2023, 2018 first second one one March 2023 On March 1, 2023, may |
Note 11 - Restatement of Previo
Note 11 - Restatement of Previously Issued Consolidated Financial Statements | 12 Months Ended |
Dec. 31, 2022 | |
Notes to Financial Statements | |
Error Correction [Text Block] | Note 11 Revised Interim Financial Information The following tables represent amounts previously reported and revised as a result of the immaterial error associated with the accounting for share-based compensation. See Note 2 As of and For the Three Months Ended March 31, 2022 Condensed Balance Sheet As Previously Reported Adjusted As Revised Total assets 39,409,431 - 39,409,431 Total liabilities 2,384,817 - 2,384,817 Common stock 47,879 - 47,879 Additional paid-in capital 120,717,072 656,678 121,373,750 Accumulated deficit (83,740,337 ) (656,678 ) (84,397,015 ) Total stockholders' equity 37,024,614 - 37,024,614 As of and For the Three Months Ended June 30, 2022 Condensed Balance Sheet As Previously Reported Adjusted As Revised Total assets 34,565,123 - 34,565,123 Total liabilities 2,153,838 - 2,153,838 Common stock 47,898 - 47,898 Additional paid-in capital 121,273,050 1,251,995 122,525,045 Accumulated deficit (88,909,663 ) (1,251,995 ) (90,161,658 ) Total stockholders' equity 32,411,285 - 32,411,285 As of and For the Three Months Ended September 30, 2022 Condensed Balance Sheet As Previously Reported Adjusted As Revised Total assets 29,945,826 - 29,945,826 Total liabilities 2,457,311 - 2,457,311 Common stock 48,020 - 48,020 Additional paid-in capital 122,432,935 1,311,780 123,744,715 Accumulated deficit (94,992,440 ) (1,311,780 ) (96,304,220 ) Total stockholders' equity 27,488,515 - 27,488,515 As of and For the Three Months Ended March 31, 2022 Condensed Statement of Operations As Previously Reported Adjusted As Revised Revenues - - - Depreciation 6,730 - 6,730 Research and development 1,860,837 179,389 2,040,226 General and administrative 3,855,796 (592,055 ) 3,263,741 Total costs and expenses 5,723,363 (412,667 ) 5,310,696 Operating (loss) gain (5,723,363 ) 412,667 (5,310,696 ) Interest income 879 - 879 Net Loss (5,722,484 ) 412,667 (5,309,817 ) Loss per share (0.12 ) 0.01 (0.11 ) Weighted average common shares outstanding 47,879,597 47,879,597 As of and For the Three Months Ended June 30, 2022 As of and For the Six Months Ended June 30, 2022 Condensed Statement of Operations As Previously Reported Adjusted As Revised As Previously Reported Adjusted As Revised Revenues - - - - - - Depreciation 6,543 - 6,543 13,273 - 13,273 Research and development 2,737,028 189,899 2,926,927 4,597,865 369,288 4,967,153 General and administrative 2,431,499 405,417 2,836,916 6,287,295 (186,638 ) 6,100,657 Total costs and expenses 5,175,070 595,316 5,770,386 10,898,433 182,650 11,081,083 Operating loss (5,175,070 ) (595,316 ) (5,770,386 ) (10,898,433 ) (182,650 ) (11,081,083 ) Interest income 5,744 - 5,744 6,623 - 6,623 Net Loss (5,169,326 ) (595,316 ) (5,764,642 ) (10,891,810 ) (182,650 ) (11,074,460 ) Loss per share (0.11 ) (0.01 ) (0.12 ) (0.23 ) (0.00 ) (0.23 ) Weighted average common shares outstanding 47,893,404 47,893,404 47,892,919 47,892,919 As of and For the Three Months Ended September 30, 2022 As of and For the Nine Months Ended September 30, 2022 Condensed Statement of Operations As Previously Reported Adjusted As Revised As Previously Reported Adjusted As Revised Revenues - - - - - - Depreciation 6,224 - 6,224 19,497 - 19,497 Research and development 3,593,309 (435,578 ) 3,157,731 8,191,174 (66,290 ) 8,124,884 General and administrative 2,511,121 495,363 3,006,484 8,798,416 308,725 9,107,141 Total costs and expenses 6,110,654 59,785 6,170,439 17,009,087 242,435 17,251,522 Operating loss (6,110,654 ) (59,785 ) (6,170,439 ) (17,009,087 ) (242,435 ) (17,251,522 ) Interest income 27,877 - 27,877 34,500 - 34,500 Net Loss (6,082,777 ) (59,785 ) (6,142,562 ) (16,974,587 ) (242,435 ) (17,217,022 ) Loss per share (0.13 ) (0.00 ) (0.13 ) (0.35 ) (0.01 ) (0.36 ) Weighted average common shares outstanding 47,984,724 47,984,724 47,919,626 47,919,626 |
Significant Accounting Policies
Significant Accounting Policies (Policies) | 12 Months Ended |
Dec. 31, 2022 | |
Accounting Policies [Abstract] | |
Correction of Error [Policy Text Block] | Correction of Immaterial Error Subsequent to the issuance of the Company's 2021 March 30, 2022, not 2021. In accordance with Staff Accounting Bulletin (“SAB”) No. 99, No. 108, not not December 31, 2021 Balance Sheet As Previously Reported Adjusted As Revised Total assets 42,862,286 - 42,862,286 Total liabilities 1,585,295 - 1,585,295 Common stock 47,874 - 47,874 Additional paid-in capital 119,246,970 1,069,345 120,316,315 Accumulated deficit (78,017,853) (1,069,345) (79,087,198) Total stockholders' equity 41,276,991 - 41,276,991 For the Year ended December 31, 2021 Statement of Operations As Previously Reported Adjusted As Revised Revenues - - - Depreciation 22,534 22,534 Research and development 8,607,751 363,114 8,970,865 General and administrative 10,970,472 706,231 11,676,703 Total costs and expenses 19,600,757 1,069,345 20,670,102 Operating loss (19,600,757) (1,069,345) (20,670,102) Interest income 5,133 - 5,133 Net Loss (19,595,624) (1,069,345) (20,664,969) Loss per share (0.42) (0.02) (0.44) Weighted average common shares outstanding 47,097,251 47,097,251 |
Use of Estimates, Policy [Policy Text Block] | Use of Estimates The preparation of our financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. |
Cash and Cash Equivalents, Policy [Policy Text Block] | Cash We consider all highly liquid short-term investments with an initial maturity of three $250,000 December 31, 2022 December 31, 2021 |
Fair Value of Financial Instruments, Policy [Policy Text Block] | Fair Value of Financial Instruments The carrying amounts reported in the balance sheet for cash, accounts receivable, accounts payable and accrued expenses approximate fair value because of the immediate or short-term maturity of these financial instruments. Accounting Standards Codification ("ASC") 820, 820’s 820 Level 1: Quoted prices for identical instruments in active markets. Level 2: Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not Level 3: Instruments with primarily unobservable value drivers. |
Property, Plant and Equipment, Policy [Policy Text Block] | Property and Equipment Furniture and equipment are stated at cost. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets, which range from three five |
Research and Development Expense, Policy [Policy Text Block] | Research and Development Materials Costs Research and development expenditures consist of costs incurred to conduct research, develop engineering materials for further study, and develop clinical strategies for current and future programs. These costs include payments to collaborative research partners, manufacturing partners and consultants, and clinical strategy partners, wages and associated employee benefits, facilities, and overhead costs. These expenditures relate to our preclinical and Phase 1/2 Research and development supplies purchased and capitalized for future use were $2,864,937 and $3,022,403 at December 31, 2022 December 31, 2021 |
Intangible Assets, Finite-Lived, Policy [Policy Text Block] | Intellectual Property Intellectual property consists of legal and related costs associated with patents and other proprietary technology and rights developed, acquired, licensed by, or maintained by us that we believe contribute to a probable economic benefit toward such patents and activities. These costs incurred in connection with obtaining and maintaining intellectual property protection, such as patent applications and patent maintenance, are capitalized. Intellectual property is stated at cost, to be amortized on a straight-line basis over the estimated useful lives of the assets. |
Share-Based Payment Arrangement [Policy Text Block] | Accounting for Stock-Based Compensation We use the fair value-based method of accounting for stock-based compensation for options granted to employees, independent consultants and contractors. We measure options granted at fair value determined as of the grant date, and recognize the expense over the periods in which the related services are rendered based on the terms and conditions of the award. Generally, where the award only has a service condition, the requisite service period is the same as the vesting period. |
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] | Long-Lived Assets We review long-lived assets and certain identifiable intangibles held and used for possible impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not December 31, 2022 December 31, 2021 |
New Accounting Pronouncements, Policy [Policy Text Block] | Recent Accounting Developments Accounting pronouncements issued but not December 31, 2022 not |
Note 2 - Summary of Significa_2
Note 2 - Summary of Significant Accounting Policies (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
Notes Tables | |
Correction of Errors [Table Text Block] | December 31, 2021 Balance Sheet As Previously Reported Adjusted As Revised Total assets 42,862,286 - 42,862,286 Total liabilities 1,585,295 - 1,585,295 Common stock 47,874 - 47,874 Additional paid-in capital 119,246,970 1,069,345 120,316,315 Accumulated deficit (78,017,853) (1,069,345) (79,087,198) Total stockholders' equity 41,276,991 - 41,276,991 For the Year ended December 31, 2021 Statement of Operations As Previously Reported Adjusted As Revised Revenues - - - Depreciation 22,534 22,534 Research and development 8,607,751 363,114 8,970,865 General and administrative 10,970,472 706,231 11,676,703 Total costs and expenses 19,600,757 1,069,345 20,670,102 Operating loss (19,600,757) (1,069,345) (20,670,102) Interest income 5,133 - 5,133 Net Loss (19,595,624) (1,069,345) (20,664,969) Loss per share (0.42) (0.02) (0.44) Weighted average common shares outstanding 47,097,251 47,097,251 |
Note 4 - Equity (Tables)
Note 4 - Equity (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
Notes Tables | |
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] | Number of Warrants Weighted Avg. Exercise Price Outstanding at January 1, 2021 2,154,747 $ 4.37 Issued 50,000 5.29 Cancelled or expired — — Exercised — — Outstanding at December 31, 2021 2,204,747 $ 4.39 Issued 103,000 1.54 Cancelled or expired 146,326 3.79 Exercised 13,643 0.50 Outstanding at December 31, 2022 2,147,778 $ 4.32 Exercisable at December 31, 2022 1,901,945 $ 4.59 |
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] | Expected term (in years): 10 Risk-free rate: 0.07% – 4.77% Volatility: 75.98% – 88.38% Dividend yield: 0% |
Share-Based Payment Arrangement, Option, Activity [Table Text Block] | Number of Shares Weighted Avg. Exercise Price Outstanding at January 1, 2021 6,844,069 $ 2.81 Options granted 2,519,628 4.26 Options exercised 670,889 1.01 Options expired 118,507 3.00 Outstanding at December 31, 2021 8,574,301 $ 3.35 Options granted 2,983,666 2.16 Options exercised 116,973 0.02 Options expired 66,667 2.55 Outstanding at December 31, 2022 11,374,327 $ 3.08 Exercisable at December 31, 2022 6,718,035 $ 3.23 |
Note 9 - Income Taxes (Tables)
Note 9 - Income Taxes (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
Notes Tables | |
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] | Income tax provision at the federal statutory rate 21 % Effect of operating losses (21 )% 0 % |
Note 11 - Restatement of Prev_2
Note 11 - Restatement of Previously Issued Consolidated Financial Statements (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
Notes Tables | |
Schedule of Error Corrections and Prior Period Adjustments [Table Text Block] | As of and For the Three Months Ended March 31, 2022 Condensed Balance Sheet As Previously Reported Adjusted As Revised Total assets 39,409,431 - 39,409,431 Total liabilities 2,384,817 - 2,384,817 Common stock 47,879 - 47,879 Additional paid-in capital 120,717,072 656,678 121,373,750 Accumulated deficit (83,740,337 ) (656,678 ) (84,397,015 ) Total stockholders' equity 37,024,614 - 37,024,614 As of and For the Three Months Ended June 30, 2022 Condensed Balance Sheet As Previously Reported Adjusted As Revised Total assets 34,565,123 - 34,565,123 Total liabilities 2,153,838 - 2,153,838 Common stock 47,898 - 47,898 Additional paid-in capital 121,273,050 1,251,995 122,525,045 Accumulated deficit (88,909,663 ) (1,251,995 ) (90,161,658 ) Total stockholders' equity 32,411,285 - 32,411,285 As of and For the Three Months Ended September 30, 2022 Condensed Balance Sheet As Previously Reported Adjusted As Revised Total assets 29,945,826 - 29,945,826 Total liabilities 2,457,311 - 2,457,311 Common stock 48,020 - 48,020 Additional paid-in capital 122,432,935 1,311,780 123,744,715 Accumulated deficit (94,992,440 ) (1,311,780 ) (96,304,220 ) Total stockholders' equity 27,488,515 - 27,488,515 As of and For the Three Months Ended March 31, 2022 Condensed Statement of Operations As Previously Reported Adjusted As Revised Revenues - - - Depreciation 6,730 - 6,730 Research and development 1,860,837 179,389 2,040,226 General and administrative 3,855,796 (592,055 ) 3,263,741 Total costs and expenses 5,723,363 (412,667 ) 5,310,696 Operating (loss) gain (5,723,363 ) 412,667 (5,310,696 ) Interest income 879 - 879 Net Loss (5,722,484 ) 412,667 (5,309,817 ) Loss per share (0.12 ) 0.01 (0.11 ) Weighted average common shares outstanding 47,879,597 47,879,597 As of and For the Three Months Ended June 30, 2022 As of and For the Six Months Ended June 30, 2022 Condensed Statement of Operations As Previously Reported Adjusted As Revised As Previously Reported Adjusted As Revised Revenues - - - - - - Depreciation 6,543 - 6,543 13,273 - 13,273 Research and development 2,737,028 189,899 2,926,927 4,597,865 369,288 4,967,153 General and administrative 2,431,499 405,417 2,836,916 6,287,295 (186,638 ) 6,100,657 Total costs and expenses 5,175,070 595,316 5,770,386 10,898,433 182,650 11,081,083 Operating loss (5,175,070 ) (595,316 ) (5,770,386 ) (10,898,433 ) (182,650 ) (11,081,083 ) Interest income 5,744 - 5,744 6,623 - 6,623 Net Loss (5,169,326 ) (595,316 ) (5,764,642 ) (10,891,810 ) (182,650 ) (11,074,460 ) Loss per share (0.11 ) (0.01 ) (0.12 ) (0.23 ) (0.00 ) (0.23 ) Weighted average common shares outstanding 47,893,404 47,893,404 47,892,919 47,892,919 As of and For the Three Months Ended September 30, 2022 As of and For the Nine Months Ended September 30, 2022 Condensed Statement of Operations As Previously Reported Adjusted As Revised As Previously Reported Adjusted As Revised Revenues - - - - - - Depreciation 6,224 - 6,224 19,497 - 19,497 Research and development 3,593,309 (435,578 ) 3,157,731 8,191,174 (66,290 ) 8,124,884 General and administrative 2,511,121 495,363 3,006,484 8,798,416 308,725 9,107,141 Total costs and expenses 6,110,654 59,785 6,170,439 17,009,087 242,435 17,251,522 Operating loss (6,110,654 ) (59,785 ) (6,170,439 ) (17,009,087 ) (242,435 ) (17,251,522 ) Interest income 27,877 - 27,877 34,500 - 34,500 Net Loss (6,082,777 ) (59,785 ) (6,142,562 ) (16,974,587 ) (242,435 ) (17,217,022 ) Loss per share (0.13 ) (0.00 ) (0.13 ) (0.35 ) (0.01 ) (0.36 ) Weighted average common shares outstanding 47,984,724 47,984,724 47,919,626 47,919,626 |
Note 2 - Summary of Significa_3
Note 2 - Summary of Significant Accounting Policies (Details Textual) - USD ($) | 12 Months Ended | |
Dec. 31, 2022 | Dec. 31, 2021 | |
Cash Equivalents, at Carrying Value, Total | $ 0 | $ 0 |
Cash, Uninsured Amount | 20,679,538 | 38,392,885 |
Research and Development Assets, Current | 2,864,937 | 3,022,403 |
Impairment, Long-Lived Asset, Held-for-Use, Total | $ 0 | $ 0 |
Minimum [Member] | ||
Property, Plant and Equipment, Useful Life (Year) | 3 years | |
Maximum [Member] | ||
Property, Plant and Equipment, Useful Life (Year) | 5 years |
Note 2 - Summary of Significa_4
Note 2 - Summary of Significant Accounting Policies - Correction of Immaterial Error (Details) - USD ($) | 3 Months Ended | 6 Months Ended | 9 Months Ended | 12 Months Ended | |||||
Sep. 30, 2022 | Jun. 30, 2022 | Mar. 31, 2021 | Jun. 30, 2022 | Sep. 30, 2022 | Dec. 31, 2022 | Dec. 31, 2021 | Mar. 31, 2022 | Dec. 31, 2020 | |
Total assets | $ 29,945,826 | $ 34,565,123 | $ 34,565,123 | $ 29,945,826 | $ 25,085,027 | $ 42,862,286 | $ 39,409,431 | ||
Total liabilities | 2,457,311 | 2,153,838 | 2,153,838 | 2,457,311 | 1,585,295 | 2,384,817 | |||
Common stock | 48,020 | 47,898 | 47,898 | 48,020 | 48,106 | 47,874 | 47,879 | ||
Additional paid-in capital | 123,744,715 | 122,525,045 | 122,525,045 | 123,744,715 | 125,054,453 | 120,316,315 | 121,373,750 | ||
Accumulated deficit | (96,304,220) | (90,161,658) | (90,161,658) | (96,304,220) | (102,827,819) | (79,087,198) | (84,397,015) | ||
Total stockholders' equity | 27,488,515 | 32,411,285 | 32,411,285 | 27,488,515 | 22,274,740 | 41,276,991 | 37,024,614 | $ 30,916,490 | |
Depreciation | 6,224 | 6,543 | $ 6,730 | 13,273 | 19,497 | 25,575 | 22,534 | ||
Research and development | 3,157,731 | 2,926,927 | 2,040,226 | 4,967,153 | 8,124,884 | 11,510,074 | 8,970,865 | ||
General and administrative | 3,006,484 | 2,836,916 | 3,263,741 | 6,100,657 | 9,107,141 | 12,295,070 | 11,676,703 | ||
Total costs and expenses | 6,170,439 | 5,770,386 | 5,310,696 | 11,081,083 | 17,251,522 | 23,830,719 | 20,670,102 | ||
Operating loss | (6,170,439) | (5,770,386) | (5,310,696) | (11,081,083) | (17,251,522) | (23,830,719) | (20,670,102) | ||
Interest income | 27,877 | 5,744 | 879 | 6,623 | 34,500 | 90,098 | 5,133 | ||
Net Loss | $ (6,142,562) | $ (5,764,642) | $ (5,309,817) | $ (11,074,460) | $ (17,217,022) | $ (23,740,621) | $ (20,664,969) | ||
Loss per share (in dollars per share) | $ (0.13) | $ (0.12) | $ (0.11) | $ (0.23) | $ (0.36) | $ (0.50) | $ (0.44) | ||
Weighted average common shares outstanding (in shares) | 47,952,100 | 47,097,251 | |||||||
Previously Reported [Member] | |||||||||
Total assets | $ 29,945,826 | $ 34,565,123 | $ 34,565,123 | $ 29,945,826 | $ 42,862,286 | 39,409,431 | |||
Total liabilities | 2,457,311 | 2,153,838 | 2,153,838 | 2,457,311 | 1,585,295 | 2,384,817 | |||
Common stock | 48,020 | 47,898 | 47,898 | 48,020 | 47,874 | 47,879 | |||
Additional paid-in capital | 122,432,935 | 121,273,050 | 121,273,050 | 122,432,935 | 119,246,970 | 120,717,072 | |||
Accumulated deficit | (94,992,440) | (88,909,663) | (88,909,663) | (94,992,440) | (78,017,853) | (83,740,337) | |||
Total stockholders' equity | 27,488,515 | 32,411,285 | 32,411,285 | 27,488,515 | 41,276,991 | $ 37,024,614 | |||
Depreciation | 6,224 | 6,543 | $ 6,730 | 13,273 | 19,497 | 22,534 | |||
Research and development | 3,593,309 | 2,737,028 | 1,860,837 | 4,597,865 | 8,191,174 | 8,607,751 | |||
General and administrative | 2,511,121 | 2,431,499 | 3,855,796 | 6,287,295 | 8,798,416 | 10,970,472 | |||
Total costs and expenses | 6,110,654 | 5,175,070 | 5,723,363 | 10,898,433 | 17,009,087 | 19,600,757 | |||
Operating loss | (6,110,654) | (5,175,070) | (5,723,363) | (10,898,433) | (17,009,087) | (19,600,757) | |||
Interest income | 27,877 | 5,744 | 879 | 6,623 | 34,500 | 5,133 | |||
Net Loss | $ (6,082,777) | $ (5,169,326) | $ (5,722,484) | $ (10,891,810) | $ (16,974,587) | $ (19,595,624) | |||
Loss per share (in dollars per share) | $ (0.13) | $ (0.11) | $ (0.12) | $ (0.23) | $ (0.35) | $ (0.42) | |||
Weighted average common shares outstanding (in shares) | 47,097,251 | ||||||||
Revision of Prior Period, Adjustment [Member] | |||||||||
Additional paid-in capital | $ 1,069,345 | ||||||||
Accumulated deficit | (1,069,345) | ||||||||
Research and development | 363,114 | ||||||||
General and administrative | 706,231 | ||||||||
Total costs and expenses | 1,069,345 | ||||||||
Operating loss | (1,069,345) | ||||||||
Net Loss | $ (1,069,345) | ||||||||
Loss per share (in dollars per share) | $ (0.02) |
Note 4 - Equity (Details Textua
Note 4 - Equity (Details Textual) - USD ($) | 1 Months Ended | 12 Months Ended | ||||||||||
Mar. 01, 2023 | Jan. 01, 2023 | Nov. 18, 2022 | Jan. 01, 2022 | Feb. 10, 2021 | Jan. 01, 2021 | Mar. 31, 2023 | Jan. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | Apr. 03, 2018 | |
Shares Issued, Price Per Share (in dollars per share) | $ 0.02 | |||||||||||
Proceeds from Issuance of Common Stock | $ 6,426 | $ 25,677,911 | ||||||||||
Stock Issued During Period, Value, Issued for Services | $ 163,232 | $ 156,045 | ||||||||||
Stock Issued During Period, Shares, Exercise of Cashless Warrants (in shares) | 13,643 | |||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in shares) | 116,973 | 670,889 | ||||||||||
Stock Issued During Period, Value, Stock Options Exercised | $ 677,912 | |||||||||||
Stock Issued During Period, Shares, Warrants Issued (in shares) | 86,138 | |||||||||||
Preferred Stock, Shares Authorized (in shares) | 10,000,000 | |||||||||||
Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ 0.001 | |||||||||||
Preferred Stock, Shares Outstanding, Ending Balance (in shares) | 0 | |||||||||||
Common Stock, Shares Authorized (in shares) | 200,000,000 | 200,000,000 | 200,000,000 | |||||||||
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ 0.001 | $ 0.001 | $ 0.001 | |||||||||
Common Stock, Shares, Outstanding, Ending Balance (in shares) | 48,105,962 | 47,874,708 | ||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 4.32 | $ 4.39 | $ 4.37 | |||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, Ending Balance (in shares) | 11,374,327 | 8,574,301 | 6,844,069 | |||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year) | 10 years | |||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance (in dollars per share) | $ 3.08 | $ 3.35 | $ 2.81 | |||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) | 2,983,666 | 2,519,628 | ||||||||||
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share) | $ 2.16 | $ 4.26 | ||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Total (in shares) | 66,667 | 118,507 | ||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price (in dollars per share) | $ 2.55 | $ 3 | ||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term (Year) | 7 years 29 days | 7 years 2 months 26 days | ||||||||||
Class of Warrant or Right, Outstanding (in shares) | 2,147,778 | 2,204,747 | 2,154,747 | |||||||||
The 2018 Equity Incentive Plan [Member] | ||||||||||||
Share Based Compensation Arrangement By Share Based Payment Award, Percentage Applied on Outstanding Shares of Common Stock For Automatically Increase on Each Year | 5% | |||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares) | 2,393,735 | 2,155,884 | ||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares) | 481,772 | |||||||||||
The 2018 Employee Stock Purchase Plan [Member] | ||||||||||||
Share Based Compensation Arrangement By Share Based Payment Award, Percentage Applied on Outstanding Shares of Common Stock For Automatically Increase on Each Year | 2% | |||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares) | 208,050 | |||||||||||
Excluding the 2018 Equity Incentive Plan [Member] | ||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, Ending Balance (in shares) | 950,000 | |||||||||||
Time Based Options [Member] | ||||||||||||
Share-based Payment Arrangement, Expense, Future Milestone | $ 90,689 | |||||||||||
Performance Shares [Member] | ||||||||||||
Share-based Payment Arrangement, Expense, Future Milestone | $ 300,000 | |||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, Ending Balance (in shares) | 0 | |||||||||||
Share-Based Payment Arrangement, Option [Member] | ||||||||||||
Share-Based Payment Arrangement, Expense | $ 4,700,000 | $ 5,400,000 | ||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value | 4,600,000 | $ 5,200,000 | ||||||||||
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total | $ 6,500,000 | |||||||||||
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year) | 1 year 9 months 3 days | |||||||||||
Warrant For Service Provider [Member] | ||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 50,000 | |||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 1.38 | |||||||||||
Warrant For Service Provider 2 [Member] | ||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 50,000 | |||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 1.49 | |||||||||||
Warrant for Services Provided at IPO [Member] | ||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 3,000 | |||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 5 | |||||||||||
Vesting of Warrants For Service Provider [Member] | ||||||||||||
Share-Based Payment Arrangement, Expense | $ 55,612 | |||||||||||
Bear Creek Capital Warrant One [Member] | ||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 25,000 | |||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 7.22 | |||||||||||
Bear Creek Capital Warrant Two [Member] | ||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 25,000 | |||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 3.36 | |||||||||||
Bear Creek Capital Warrants [Member] | ||||||||||||
Share-Based Payment Arrangement, Expense | $ 200,282 | |||||||||||
Performance-based Warrant [Member] | ||||||||||||
Class of Warrant or Right, Outstanding (in shares) | 1 | |||||||||||
Warrant, Nonvested Award, Cost Not yet Recognized, Amount | $ 300,000 | |||||||||||
Scientific Advisory Board Chairman [Member] | ||||||||||||
Stock Issued During Period, Shares, Issued for Services (in shares) | 20,000 | |||||||||||
Stock Issued During Period, Value, Issued for Services | $ 42,400 | |||||||||||
Consultant [Member] | ||||||||||||
Stock Issued During Period, Shares, Issued for Services (in shares) | 76,752 | |||||||||||
Stock Issued During Period, Value, Issued for Services | $ 99,010 | $ 154,648 | ||||||||||
Maximum [Member] | ||||||||||||
Shares Issued, Price Per Share (in dollars per share) | $ 2.15 | |||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Month) | 48 months | |||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance (in dollars per share) | $ 9.80 | |||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value (in dollars per share) | 7.93 | |||||||||||
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share) | 3.50 | 7.22 | ||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price (in dollars per share) | $ 3.66 | 7.22 | ||||||||||
Minimum [Member] | ||||||||||||
Shares Issued, Price Per Share (in dollars per share) | 0.015 | |||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Month) | 12 months | |||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance (in dollars per share) | $ 0.298 | |||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value (in dollars per share) | 0.24 | |||||||||||
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share) | 1.27 | 2.72 | ||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price (in dollars per share) | $ 2 | $ 1.45 | ||||||||||
Subsequent Event [Member] | The 2018 Equity Incentive Plan [Member] | ||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares) | 2,405,298 | |||||||||||
Subsequent Event [Member] | Scientific Advisory Board Chairman [Member] | ||||||||||||
Stock Issued During Period, Shares, Issued for Services (in shares) | 5,000 | |||||||||||
Registered Direct Offering [Member] | Subsequent Event [Member] | ||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 3,809,524 | |||||||||||
Proceeds from Issuance or Sale of Equity, Total | $ 3,600,000 | $ 3,600,000 | ||||||||||
Registered Direct Offering [Member] | Investors [Member] | ||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 4,000,000 | |||||||||||
Shares Issued, Price Per Share (in dollars per share) | $ 6.25 | |||||||||||
Proceeds from Issuance of Common Stock | $ 23,200,000 | |||||||||||
The 2022 ATM Facility [Member] | ||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 3,886 | |||||||||||
Proceeds from Issuance of Common Stock | $ 4,532 | |||||||||||
Brokerage Commissions, Percentage of Gross Proceeds | 3% | |||||||||||
The 2022 ATM Facility [Member] | Maximum [Member] | ||||||||||||
Common Stock, Shares Authorized, Value | $ 50,000,000 | |||||||||||
The 2022 ATM Facility [Member] | Subsequent Event [Member] | ||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 53,592 | |||||||||||
Proceeds from Issuance of Common Stock | $ 78,355 |
Note 4 - Equity - Common Stock
Note 4 - Equity - Common Stock Purchase Warrant Activity (Details) - $ / shares | 12 Months Ended | |
Dec. 31, 2022 | Dec. 31, 2021 | |
Outstanding, number of warrants (in shares) | 2,204,747 | 2,154,747 |
Outstanding, weighted average exercise price (in dollars per share) | $ 4.39 | $ 4.37 |
Issued, number of warrants (in shares) | 103,000 | 50,000 |
Issued, weighted average exercise price (in dollars per share) | $ 1.54 | $ 5.29 |
Cancelled or expired, number of warrants (in shares) | 146,326 | 0 |
Cancelled or expired, weighted average exercise price (in dollars per share) | $ 3.79 | $ 0 |
Exercised, number of warrants (in shares) | 13,643 | 0 |
Exercised, weighted average exercise price (in dollars per share) | $ 0.50 | $ 0 |
Outstanding, number of warrants (in shares) | 2,147,778 | 2,204,747 |
Outstanding, weighted average exercise price (in dollars per share) | $ 4.32 | $ 4.39 |
Exercisable, number of warrants (in shares) | 1,901,945 | |
Exercisable, weighted average exercise price (in dollars per share) | $ 4.59 |
Note 4 - Equity - Assumptions (
Note 4 - Equity - Assumptions (Details) | 12 Months Ended |
Dec. 31, 2022 | |
Expected term (in years): (Year) | 10 years |
Dividend yield: | 0% |
Minimum [Member] | |
Risk-free rate: | 0.07% |
Volatility: | 75.98% |
Maximum [Member] | |
Risk-free rate: | 4.77% |
Volatility: | 88.38% |
Note 4 - Equity - Stock Option
Note 4 - Equity - Stock Option Activity (Details) - $ / shares | 12 Months Ended | |
Dec. 31, 2022 | Dec. 31, 2021 | |
Outstanding, number of shares (in shares) | 8,574,301 | 6,844,069 |
Outstanding, weighted average exercise price (in dollars per share) | $ 3.35 | $ 2.81 |
Options granted, number of shares (in shares) | 2,983,666 | 2,519,628 |
Options granted, weighted average exercise price (in dollars per share) | $ 2.16 | $ 4.26 |
Options exercised, number of shares (in shares) | 116,973 | 670,889 |
Options exercised, weighted average exercise price (in dollars per share) | $ 0.02 | $ 1.01 |
Options expired or cancelled, number of shares (in shares) | 66,667 | 118,507 |
Options expired, weighted average exercise price (in dollars per share) | $ 2.55 | $ 3 |
Outstanding, number of shares (in shares) | 11,374,327 | 8,574,301 |
Outstanding, weighted average exercise price (in dollars per share) | $ 3.08 | $ 3.35 |
Exercisable, number of shares (in shares) | 6,718,035 | |
Exercisable, weighted average exercise price (in dollars per share) | $ 3.23 |
Note 5 - 401(k) Savings Trans_2
Note 5 - 401(k) Savings Transactions (Details Textual) | 12 Months Ended |
Dec. 31, 2022 USD ($) | |
Defined Contribution Plan, Cost | $ 74,281 |
Note 7 - Commitments and Cont_2
Note 7 - Commitments and Contingencies (Details Textual) - USD ($) | 1 Months Ended | 3 Months Ended | 12 Months Ended | |||||||
Sep. 30, 2022 | Jul. 31, 2018 | Mar. 31, 2017 | Dec. 31, 2009 | Dec. 31, 2022 | Dec. 29, 2022 | Nov. 22, 2022 | Jul. 31, 2022 | Mar. 03, 2021 | Feb. 11, 2020 | |
Other Commitment, Total | $ 340,000 | |||||||||
License Agreement Terms [Member] | ||||||||||
License Agreement Milestone Payment | $ 6,150,000 | |||||||||
National Institute of Health [Member] | ||||||||||
Royalty on Sales, Percentage | 1% | |||||||||
Royalty Term (Year) | 21 years | |||||||||
Royalty Payment, Annual Minimum | $ 20,000 | |||||||||
Payment for Contingent Consideration Liability, Operating Activities | $ 240,000 | |||||||||
Contingent Payments Annual Increase | $ 20,000 | |||||||||
Research Agreement [Member] | MD Anderson [Member] | ||||||||||
Long Term Contract, Estimated Cost | $ 2,900,000 | $ 2,000,000 | ||||||||
License Agreement [Member] | University of Pittsburgh [Member] | ||||||||||
Licensing Fee, Amount | $ 25,000 | $ 25,000 | $ 25,000 | |||||||
Annual Maintenance Fee, First Three Years, Amount | 25,000 | 25,000 | 25,000 | |||||||
Annual Maintenance Fee, After Year Three, Amount | 40,000 | 40,000 | 40,000 | |||||||
Annual Royalty Payment Per Year, Minimum | $ 250,000 | $ 250,000 | $ 250,000 | |||||||
Share of Non-Royalty Sublicense Income, Percent | 20% | 20% | 20% | |||||||
License Agreement [Member] | University of Pittsburgh [Member] | Dosing of First Human Patient in a Phase I Clinical Trial [Member] | ||||||||||
Milestone Payment | $ 3,975,000 | |||||||||
License Agreement [Member] | University of Pittsburgh [Member] | Usage of a Glucagon Promoter and Gene Therapy Technologies to Potentially Treat Type 1 Diabetes [Member] | ||||||||||
Milestone Payment | $ 3,975,000 | |||||||||
License Agreement [Member] | University of Pittsburgh [Member] | Usage of a Glucagon Promoter and Gene Therapy Technologies to Potentially Treat Type 2 Diabetes [Member] | ||||||||||
Milestone Payment | $ 3,975,000 | |||||||||
License Agreement [Member] | University of Pittsburgh [Member] | Minimum [Member] | ||||||||||
Royalty Percent, Licensed Technology Covered by Patent | 1.50% | 1.50% | 1.50% | |||||||
License Agreement [Member] | University of Pittsburgh [Member] | Maximum [Member] | ||||||||||
Royalty Percent, Licensed Technology Covered by Patent | 3% | 3% | 3% | |||||||
Development and Manufacturing of GMP Grade Materials [Member] | ||||||||||
Development Services Agreement, Expected Total Project Cost | $ 2,500,000 |
Note 9 - Income Taxes (Details
Note 9 - Income Taxes (Details Textual) $ in Millions | Dec. 31, 2022 USD ($) |
Operating Loss Carryforwards | $ 68.9 |
Note 9 - Income Taxes - Income
Note 9 - Income Taxes - Income Tax Reconciliation (Details) | 12 Months Ended |
Dec. 31, 2022 | |
Income tax provision at the federal statutory rate | 21% |
Effect of operating losses | (21.00%) |
Effective Income Tax Rate Reconciliation, Percent, Total | 0% |
Note 10 - Subsequent Events (De
Note 10 - Subsequent Events (Details Textual) - USD ($) | 1 Months Ended | 12 Months Ended | |||||||||||
Mar. 01, 2023 | Feb. 18, 2023 | Jan. 30, 2023 | Jan. 01, 2023 | Nov. 18, 2022 | Jan. 01, 2022 | Jan. 01, 2021 | Mar. 31, 2023 | Jan. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | Feb. 16, 2023 | Dec. 31, 2020 | |
Proceeds from Issuance of Common Stock | $ 6,426 | $ 25,677,911 | |||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) | 2,983,666 | 2,519,628 | |||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 4.32 | $ 4.39 | $ 4.37 | ||||||||||
The 2022 ATM Facility [Member] | |||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 3,886 | ||||||||||||
Proceeds from Issuance of Common Stock | $ 4,532 | ||||||||||||
Scientific Advisory Board Chairman [Member] | |||||||||||||
Stock Issued During Period, Shares, Issued for Services (in shares) | 20,000 | ||||||||||||
The 2018 Equity Incentive Plan [Member] | |||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares) | 2,393,735 | 2,155,884 | |||||||||||
Subsequent Event [Member] | Consultant Warrants [Member] | |||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 30,000 | ||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 1.65 | ||||||||||||
Subsequent Event [Member] | Warrants Issued with Registered Direct Offering [Member] | |||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 3,809,524 | ||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 1.10 | ||||||||||||
Warrants and Rights Outstanding, Term (Year) | 5 years | ||||||||||||
Subsequent Event [Member] | The 2022 ATM Facility [Member] | |||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 53,592 | ||||||||||||
Proceeds from Issuance of Common Stock | $ 78,355 | ||||||||||||
Subsequent Event [Member] | Registered Direct Offering [Member] | |||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 3,809,524 | ||||||||||||
Equity Offering, Combined Purchase Price (in dollars per share) | $ 1.05 | ||||||||||||
Proceeds from Issuance or Sale of Equity, Total | $ 3,600,000 | $ 3,600,000 | |||||||||||
Subsequent Event [Member] | Scientific Advisory Board Chairman [Member] | |||||||||||||
Stock Issued During Period, Shares, Issued for Services (in shares) | 5,000 | ||||||||||||
Subsequent Event [Member] | The 2018 Equity Incentive Plan [Member] | |||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares) | 2,405,298 | ||||||||||||
Subsequent Event [Member] | The 2018 Equity Incentive Plan [Member] | Share-Based Payment Arrangement, Employee [Member] | |||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) | 82,500 | ||||||||||||
Subsequent Event [Member] | The 2018 Equity Incentive Plan [Member] | Non-executive Employees [Member] | Restricted Stock Units (RSUs) [Member] | |||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted (in shares) | 353,195 | ||||||||||||
Subsequent Event [Member] | The 2018 Equity Incentive Plan [Member] | Non-executive Employees [Member] | Restricted Stock Units (RSUs) [Member] | Share-Based Payment Arrangement, Tranche One [Member] | |||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage | 50% | ||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Month) | 1 year | ||||||||||||
Subsequent Event [Member] | The 2018 Equity Incentive Plan [Member] | Non-executive Employees [Member] | Restricted Stock Units (RSUs) [Member] | Share-Based Payment Arrangement, Tranche Two [Member] | |||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage | 50% | ||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Month) | 2 years | ||||||||||||
Subsequent Event [Member] | The 2018 Equity Incentive Plan [Member] | Executive Officer [Member] | |||||||||||||
Annual Incentive Awards | $ 972,720 | ||||||||||||
Subsequent Event [Member] | The 2018 Equity Incentive Plan [Member] | Executive Officer [Member] | Restricted Stock Units (RSUs) [Member] | |||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted (in shares) | 1,560,000 | ||||||||||||
Subsequent Event [Member] | The 2018 Equity Incentive Plan [Member] | Executive Officer [Member] | Restricted Stock Units (RSUs) [Member] | Share-Based Payment Arrangement, Tranche One [Member] | |||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage | 50% | ||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Month) | 1 year | ||||||||||||
Subsequent Event [Member] | The 2018 Equity Incentive Plan [Member] | Executive Officer [Member] | Restricted Stock Units (RSUs) [Member] | Share-Based Payment Arrangement, Tranche Two [Member] | |||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage | 50% | ||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Month) | 2 years |
Note 11 - Restatement of Prev_3
Note 11 - Restatement of Previously Issued Consolidated Financial Statements - Restatement (Details) - USD ($) | 3 Months Ended | 6 Months Ended | 9 Months Ended | 12 Months Ended | |||||
Sep. 30, 2022 | Jun. 30, 2022 | Mar. 31, 2021 | Jun. 30, 2022 | Sep. 30, 2022 | Dec. 31, 2022 | Dec. 31, 2021 | Mar. 31, 2022 | Dec. 31, 2020 | |
Total assets | $ 29,945,826 | $ 34,565,123 | $ 34,565,123 | $ 29,945,826 | $ 25,085,027 | $ 42,862,286 | $ 39,409,431 | ||
Total liabilities | 2,457,311 | 2,153,838 | 2,153,838 | 2,457,311 | 1,585,295 | 2,384,817 | |||
Common stock | 48,020 | 47,898 | 47,898 | 48,020 | 48,106 | 47,874 | 47,879 | ||
Additional paid-in capital | 123,744,715 | 122,525,045 | 122,525,045 | 123,744,715 | 125,054,453 | 120,316,315 | 121,373,750 | ||
Accumulated deficit | (96,304,220) | (90,161,658) | (90,161,658) | (96,304,220) | (102,827,819) | (79,087,198) | (84,397,015) | ||
Total stockholders' equity | 27,488,515 | 32,411,285 | 32,411,285 | 27,488,515 | 22,274,740 | 41,276,991 | 37,024,614 | $ 30,916,490 | |
Revenues | 0 | 0 | $ 0 | 0 | 0 | 0 | 0 | ||
Depreciation | 6,224 | 6,543 | 6,730 | 13,273 | 19,497 | 25,575 | 22,534 | ||
Research and development | 3,157,731 | 2,926,927 | 2,040,226 | 4,967,153 | 8,124,884 | 11,510,074 | 8,970,865 | ||
General and administrative | 3,006,484 | 2,836,916 | 3,263,741 | 6,100,657 | 9,107,141 | 12,295,070 | 11,676,703 | ||
Total costs and expenses | 6,170,439 | 5,770,386 | 5,310,696 | 11,081,083 | 17,251,522 | 23,830,719 | 20,670,102 | ||
Operating (loss) gain | (6,170,439) | (5,770,386) | (5,310,696) | (11,081,083) | (17,251,522) | (23,830,719) | (20,670,102) | ||
Interest income | 27,877 | 5,744 | 879 | 6,623 | 34,500 | 90,098 | 5,133 | ||
Net Loss | $ (6,142,562) | $ (5,764,642) | $ (5,309,817) | $ (11,074,460) | $ (17,217,022) | $ (23,740,621) | $ (20,664,969) | ||
Loss per share (in dollars per share) | $ (0.13) | $ (0.12) | $ (0.11) | $ (0.23) | $ (0.36) | $ (0.50) | $ (0.44) | ||
Weighted average common shares outstanding (in shares) | 47,984,724 | 47,893,404 | 47,879,597 | 47,892,919 | 47,919,626 | ||||
Previously Reported [Member] | |||||||||
Total assets | $ 29,945,826 | $ 34,565,123 | $ 34,565,123 | $ 29,945,826 | $ 42,862,286 | 39,409,431 | |||
Total liabilities | 2,457,311 | 2,153,838 | 2,153,838 | 2,457,311 | 1,585,295 | 2,384,817 | |||
Common stock | 48,020 | 47,898 | 47,898 | 48,020 | 47,874 | 47,879 | |||
Additional paid-in capital | 122,432,935 | 121,273,050 | 121,273,050 | 122,432,935 | 119,246,970 | 120,717,072 | |||
Accumulated deficit | (94,992,440) | (88,909,663) | (88,909,663) | (94,992,440) | (78,017,853) | (83,740,337) | |||
Total stockholders' equity | 27,488,515 | 32,411,285 | 32,411,285 | 27,488,515 | 41,276,991 | 37,024,614 | |||
Revenues | 0 | 0 | $ 0 | 0 | 0 | ||||
Depreciation | 6,224 | 6,543 | 6,730 | 13,273 | 19,497 | 22,534 | |||
Research and development | 3,593,309 | 2,737,028 | 1,860,837 | 4,597,865 | 8,191,174 | 8,607,751 | |||
General and administrative | 2,511,121 | 2,431,499 | 3,855,796 | 6,287,295 | 8,798,416 | 10,970,472 | |||
Total costs and expenses | 6,110,654 | 5,175,070 | 5,723,363 | 10,898,433 | 17,009,087 | 19,600,757 | |||
Operating (loss) gain | (6,110,654) | (5,175,070) | (5,723,363) | (10,898,433) | (17,009,087) | (19,600,757) | |||
Interest income | 27,877 | 5,744 | 879 | 6,623 | 34,500 | 5,133 | |||
Net Loss | $ (6,082,777) | $ (5,169,326) | $ (5,722,484) | $ (10,891,810) | $ (16,974,587) | $ (19,595,624) | |||
Loss per share (in dollars per share) | $ (0.13) | $ (0.11) | $ (0.12) | $ (0.23) | $ (0.35) | $ (0.42) | |||
Weighted average common shares outstanding (in shares) | 47,984,724 | 47,893,404 | 47,879,597 | 47,892,919 | 47,919,626 | ||||
Revision of Prior Period, Reclassification, Adjustment [Member] | |||||||||
Total assets | $ 0 | $ 0 | $ 0 | $ 0 | 0 | ||||
Total liabilities | 0 | 0 | 0 | 0 | 0 | ||||
Common stock | 0 | 0 | 0 | 0 | 0 | ||||
Additional paid-in capital | 1,311,780 | 1,251,995 | 1,251,995 | 1,311,780 | 656,678 | ||||
Accumulated deficit | (1,311,780) | (1,251,995) | (1,251,995) | (1,311,780) | (656,678) | ||||
Total stockholders' equity | 0 | 0 | 0 | 0 | $ 0 | ||||
Revenues | 0 | 0 | $ 0 | 0 | 0 | ||||
Depreciation | 0 | 0 | 0 | 0 | 0 | ||||
Research and development | (435,578) | 189,899 | 179,389 | 369,288 | (66,290) | ||||
General and administrative | 495,363 | 405,417 | (592,055) | (186,638) | 308,725 | ||||
Total costs and expenses | 59,785 | 595,316 | (412,667) | 182,650 | 242,435 | ||||
Operating (loss) gain | (59,785) | (595,316) | 412,667 | (182,650) | (242,435) | ||||
Interest income | 0 | 0 | 0 | 0 | 0 | ||||
Net Loss | $ (59,785) | $ (595,316) | $ 412,667 | $ (182,650) | $ (242,435) | ||||
Loss per share (in dollars per share) | $ 0 | $ (0.01) | $ 0.01 | $ 0 | $ (0.01) |